Tags Archive Navigation
icon
-
Media ReleaseAveXis Announces Pricing of Public Offering of Common Stock
-
Media ReleaseAveXis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Media ReleaseAveXis to Initiate Screening for Remaining Patients in Pivotal Trial of AVXS-101 for SMA Type 1 Following Review of Preliminary Data from First Three Patients
-
Media ReleaseAveXis to Report Fourth Quarter and Full Year 2017 Financial and Operating Results
-
Media ReleaseAveXis Reports Fourth Quarter and Full Year 2017 Financial and Operating Results
-
Media ReleaseAveXis Enters into Licensing Agreement with Genethon
-
Media ReleaseAveXis Gene Therapy Awarded SAKIGAKE Designation for Spinal Muscular Atrophy Type 1
-
Media ReleaseAveXis to Present AVXS-101 Data at the Annual Meeting of the American Academy of Neurology
-
Media ReleaseAveXis Presents Initial Data from Pivotal U.S. Trial for SMA Type 1 and 24-Month Follow-Up Data from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the American Academy of Neurology
-
Media ReleaseAveXis Announces First Patient Dosed in Phase 3 Trial of AVXS-101 in Pre-Symptomatic SMA Types 1, 2 and 3
-
Media ReleaseAveXis Statement on Access to Zolgensma® (onasemnogene abeparvovec-xioi)
-
Media ReleaseAveXis Reports First Quarter 2018 Financial and Operating Results
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- › Next page